


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:


Listing of Claims:

1(Currently Amended). A pharmaceutical composition useful for the treatment of cancer comprising a compound ~~selected from~~ of the formula: ~~consisting of~~

(a)




and



(b)


wherein ~~for either formula (a) and (b)~~, R_1 is a substituted or unsubstituted lower alkyl of 1 to 10 carbon atoms, X is a naturally-occurring or non-naturally-occurring amino acid, and m is an integer of 0 to 20 ~~and wherein for formula (b), n is an integer of 1 or 2, and q is an integer of 0 or 1~~, or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable carrier.

2(Currently Amended). The composition according to claim 1, wherein X_m of ~~formula (a)~~ is:



wherein n is an integer of 1 or 2, and q is an integer of 0 or 1, and s is an integer of 0 to 19.


3(Currently Amended). The composition according to claim 1, wherein X_m of formula (a) is:



wherein n is an integer of 1 or 2, and q is an integer of 0 or 1, and s is an integer of 0 to 19.


4(Currently Amended). The composition according to claim 1, ~~wherein which is selected from the group consisting of:~~

- i. ~~said formula (a), wherein m is 0;~~
- ii. ~~said formula (a), wherein m is 0, said R_1 is a methyl group, and said compound is cystine dimethyl ester;~~
- iii. ~~said formula (a), wherein X_m of formula (a) is:~~




wherein, n is an integer of 1 or 2, and q is an integer of 0 or 1, and s is an integer of 0 to 19, X is selected from the group consisting of D-Asp, L-Asp, D-Glu and L-Glu, and m is 1; or

- iv. ~~said formula (b), wherein X_m of formula (a) is~~




~~wherein n is an integer of 1 or 2, and q is an integer of 0 or 1, and s is an integer of 0 to 19, X is selected from the group consisting of D-Asp, L-Asp, D-Glu and L-Glu, and m is 1;~~

v. ~~said formula (a), wherein X_m of formula (a) is~~



wherein, n is an integer of 1 or 2, ~~and~~ q is an integer of 0 or 1, ~~and~~ s is an integer of 0 to 19, ~~wherein~~ X is selected from the group consisting of D-Asp, L-Asp, D-Glu and L-Glu, and m is 1;

vi. ~~said formula (b), wherein X_m of formula (a) is~~



wherein n is an integer of 1 or 2, ~~and~~ q is an integer of 0 or 1, ~~and~~ s is an integer of 0 to 19, ~~wherein~~ X is selected from the group consisting of D-Asp, L-Asp, D-Glu and L-Glu, and m is 1; —

~~vii. said formula (b), wherein q is 1 and m is 0;~~

~~viii. said formula (b), wherein R_1 is a methyl group;~~

~~ix. said formula (b), wherein m is an integer from 1 to 10; and~~

~~x. said formula (b), wherein m is 1.~~

5-11(Canceled).

12(Previously Presented). The composition according to claim 1, further comprising a cytotoxic compound.

13(Previously Presented). The composition according to claim 12, wherein said cytotoxic compound is an apoptotic compound or a chemotherapeutic compound.

14(Canceled).

15(Currently Amended). The composition according to claim 1, wherein said compound of ~~Formula (a) or (b)~~ upon exposure to a susceptible cell increases the cell's intralysosomal cystine level above 0.5 nmol/mg cell protein.

16-27(Canceled).

28(Original). A pharmaceutical kit for the treatment of cancer comprising at least one composition of claim 1 in a dosage unit.

29(Canceled).

30(Currently Amended). The kit according to claim 28, wherein said compound of ~~formula (a)~~ is cystine dimethyl ester.

31(Canceled).

32(Previously Presented). The kit according to claim 28, further comprising a cytotoxic compound.

33(New). The composition according to claim 1, wherein said cancer is breast cancer.

34(New). The kit according to claim 28, wherein said cancer is breast cancer.

35(New). The kit according to claim 28, wherein said composition is formulated for administration to a cell concurrently with radiation.

36(New). The composition according to claim 1, wherein said composition is formulated for administration to a cell concurrently with radiation.